Entera Bio Ltd.
A clinical-stage company developing oral peptide and protein replacement therapies.
ENTX | US
Overview
Corporate Details
- ISIN(s):
- IL0011429839
- LEI:
- Country:
- United States of America
- Address:
- KIRYAT HADASSAH, MINRAV BUILDING, 9112002 JERUSALEM
- Website:
- https://enterabio.com/
- Sector:
- Manufacturing
Description
Entera Bio Ltd. is a clinical-stage company developing orally delivered peptide and protein replacement therapies. The company leverages its proprietary N-Tab™ technology platform, which is designed to stabilize peptides in the gastrointestinal tract and promote their absorption into the bloodstream, offering a tablet-based alternative to injections. Its development pipeline targets significant unmet medical needs. Key programs include EB613, an oral teriparatide (PTH(1-34)) for postmenopausal women with high-risk osteoporosis, and EB612 for patients with hypoparathyroidism. Other programs include an oral oxyntomodulin for obesity and an oral GLP-2 peptide for rare malabsorption conditions such as short bowel syndrome.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Entera Bio Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Entera Bio Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Entera Bio Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
